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Abstract
Background: Reduced renal function is an independent risk factor for cardiovascular disease mortality, and persistently
elevated cardiac troponin T (cTnT) is frequently observed in patients with end-stage renal disease. In the general population
the relationship between renal function and cTnT levels may not be clear because of the low sensitivity of the assay. In this
study, we investigated the level of cTnT using a highly sensitive assay (hs-cTnT) and evaluated the association of estimated
glomerular filtration rate (eGFR) with detectable hs-cTnT levels in a community-based population.
Methods: The serum hs-cTnT levels were measured in 1365 community dwelling population aged $45 years in Beijing,
China. eGFR was determined by the Chinese modifying modification of diet in renal disease (C-MDRD) equation.
Results: With the highly sensitive assay, cTnT levels were detectable ($3pg/mL) in 744 subjects (54.5%). The result showed
that eGFR was associated with Log hs-cTnT (r=20.14, P,0.001). After adjustment for the high predicted Framingham
Coronary Heart Disease (CHD) risk (10-year risk .20%) and other prognostic indicators, moderate to severe reduced eGFR
was independently associated with detectable hs-cTnT, whereas normal to mildly reduced eGFR was not independently
associated with detectable hs-cTnT. In addition, after adjustment for other risk factors, the high predicted Framingham CHD
risk was associated with detectable hs-cTnT in the subjects with different quartile levels of eGFR.
Conclusion: The levels of hs-cTnT are detectable in a community-based Chinese population and low eGFR is associated with
detectable hs-cTnT. Moreover, eGFR and high predicted Framingham CHD risk are associated with detectable hs-cTnT in
subjects with moderate-to-severe reduced renal function.
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Introduction
A reduced glomerular filtration rate is an independent risk
factor for cardiovascular disease mortality [1–2]. Meanwhile,
several large-scale prospective clinical trials have shown that the
prevalence of adverse cardiovascular disease events is increased
among patients with end-stage renal disease [3–4]. Also, persis-
tently elevated levels of cardiac biomarkers are frequently observed
in these patients [5–6], such as cardiac troponin T (cTnT), as a
highly sensitive and specific marker of myocardial damage. In the
asymptomatic general population, however, the relationship
between renal function and myocardial injury is not clear. The
clinical use of serum levels of cardiac biomarkers has limitations
because of the low sensitivity of the assay systems [7]. The
prevalence of detectable concentrations of cTnT in the general
population is approximately 0.7% with the use of conventional
assays [8].
Recently, a highly sensitive cardiac troponin T (hs-cTnT) assay
has become commercially available permitting measurement of
concentrations that are lower by a factor of 10 than those
measurable with conventional assays [9]. Indeed, as recommended
in the recent guideline for biomarker evaluation, optimal precision
(the coefficient of variation (CV) at the 99th percentile upper
reference limit for assays should be defined as #10%) and reliable
precision allows for sensitive assays [10]. cTnT with a highly
sensitive assay meets the recommendation and provides a sensitive
assay to study the relationship between renal function and
myocardial damage or subclinical myocardial damage in asymp-
tomatic subjects with normal-to-mild reduced renal function.
The Framingham Coronary Heart Disease (CHD) risk predic-
tion score is calculated by the individual variables that constitute
the risk score, including sex, age, low-density lipoprotein (LDL)-
cholesterol, SBP, DBP, history of diabetes mellitus (DM), and
current smoking [11]. Our previous study had confirmed that the
Framingham CHD risk prediction score is independently and
positively associated with detectable hs-cTnT [12]. In this study
we investigated the relationship between estimated glomerular
filtration rate (eGFR) and detectable hs-cTnT, and the role of the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38218high predicted Framingham CHD risk (10-year risk .20%) in a
community-based population in Beijing, China.
Methods
The study protocol was approved by the Ethics Committee of
the Chinese People’s Liberation Army (PLA) General Hospital
(Beijing, China). Each participant provided written informed
consent to be included in the study.
Study population
This was a community-based cross-sectional study of people
living in the Pingguoyuan area of Shijingshan district, a
metropolitan area in Beijing, China. All participants were
permanent residents of Han origin, aged $45 years, who were
recruited to the study after a routine health check-up from
September 2007 to January 2009. Subjects with bedridden status,
mental illness, malignant tumors and severe systemic diseases were
excluded from the analysis. Initially, 1,601 participants were
included. Among them, 1,503 subjects provided blood samples for
the testing of cardiac biomarkers. Of those, 6 subjects had missing
data, such as without serum lipids, blood glucose or serum
creatinine. Therefore, a total of 1,497 participants with complete
data were eligible for assessment. Eventually, after excluding 132
participants for overt vardiovascular disease, 1365 participants
formed the present study.
Questionnaire and anthropometric measurements
Information about smoking status, medication use, a history of
hypertension, DM, and coronary heart disease was obtained by
self-reporting, standardized questionnaires. This was administered
using a face-to-face counseling method. The investigation was
completed by physicians in the Department of Geriatric Cardi-
ology of the People’s Liberation Army General Hospital who were
trained by the research team.
Height, weight and circumferences of the waist and hip were
measured. The body mass index (BMI) and waist-to-hip ratio
(WHR) were calculated. BMI was calculated as weight in
kilograms divided by the height in meters squared (kg/m
2).
WHR was calculated as waist circumference (WC) divided by hip
circumference. The measurement of blood pressure was done
using a calibrated desktop sphygmomanometer (Yuyue, Arma-
mentarium Limited Company, Jiangsu, China) after participants
had been in the supine position for $5 min [13]. Blood pressure
was measured thrice consecutively, with $1 min between
measurements. The mean value of blood pressure was used for
the statistical analysis.
Biomarker measurements
Blood samples were collected in tubes containing separating gel
after overnight fasting and maintained at 4uC for #2 h before
being centrifuged at 12006 g for 15 min. Serum aliquots were
frozen at 280uC until assays were carried out.
Concentrations of fasting glucose, total cholesterol, triglyceride,
high-density lipoprotein (HDL)-cholesterol, LDL-cholesterol, uric
acid and homocysteine were determined using the enzymatic
assays (Roche Diagnostics GmbH, Mannheim, Germany) on an
autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Con-
centrations of hs-cTnT were determined using a Elecsys Troponin
T highly sensitivity assay (Roche Diagnostics GmbH, Mannheim,
Germany) by an electrochemiluminescence immunoassay method
on a Modular Analytics E170 Autoanalyzer (Roche Diagnostics).
Given enhanced sensitivity, this assay was reported in units of
picograms per milliliter (pg/mL) with an interassay coefficient of
variation of 8% at 10 pg/mL and 2.5% at 100 pg/mL [14]. The
lower detection limit of the hs-cTnT assay was 3 pg/mL
(according to manufacturer’s information), which was used as
the cut-off point in the present analysis; hs-cTnT levels less than
3 pg/mL were considered undetectable (,3.0 pg/mL). The 99th
percentile for a reference population has been reported to be
13.3 pg/mL [10]. Concentrations of the N-terminal prohormone
of brain natriuretic peptide (NT-proBNP) were determined with
an electrochemiluminescence immunoassay (Roche Diagnostics
GmbH) using a Roche analyzer. It had a measurement range of 5–
35000 pg/mL. According to manufacturer’s information, the
lower limit of detection was 5 pg/mL [15]. Concentrations of
high-sensitivity C-reactive protein (hs-CRP) were determined by
an immunoturbidimetric assay (Siemens Healthcare Diagnostics,
Los Angeles, CA, USA) using a Dimension RxL Max analyzer
(Siemens Healthcare Diagnostics). Concentrations of serum
creatinine were measured by an enzymatic assay (Roche
Diagnostics GmbH) on a Hitachi 7600 Autoanalyser (Hitachi,
Tokyo, Japan). All testing was undertaken by well-trained
personnel blinded to clinical data in the Department of
Biochemistry of Chinese PLA General Hospital.
Definition of variables
Cigarette smoking was assessed by asking each individual
whether he/she was a current smoker. A subject was considered to
have hypertension if (i) systolic blood pressure (SBP) $140 mmHg;
and/or (ii) diastolic blood pressure (DBP) $90 mmHg; and/or (iii)
the subject was taking an antihypertensive drug [16].
All participants without a history of DM were given a standard
75 g oral glucose tolerance test (OGTT). Results showed that 1286
participants had the OGTT. Fasting venous blood was collected
from participants with a history of DM to measure blood glucose.
A subject was considered to have DM if (i) fasting venous blood
glucose $7.1 mmol/L; (ii) 2 h venous blood glucose
$11.1 mmol/L; or (iii) the subject was taking a hypoglycemic
drug or insulin [17].
Renal function was evaluated by eGFR. Creatinine level was
standardized using a calibration equation: Jaffe’s kinetic method
Scr (mg/dL)=0.7956[enzymatic method Scr (mg/dL)]+0.29
[18]. eGFR was calculated using the Chinese modifying modifi-
cation of diet in renal disease (C-MDRD) equation [19]: eGFR
(mL/min/1.73 m
2)=1756standard creatinine (mg/
dL)
21.2346age (year)
20.1796(0.79 if female).
Calculation of predicted risk
The Framingham CHD risk prediction score incorporates sex,
age, LDL-cholesterol, SBP, DBP, history of DM, and current
smoking [11]. The levels of 10-year risk for the CHD events were
categorized as: low (10-year risk ,10%); moderate (10-year risk
10% to 20%); or high (10-year risk .20%) [20]. In the present
analysis, the high predicted Framingham CHD risk (10-year risk
.20%) was used as the cut-off point.
Statistical analyses
Characteristics are reported as percentages for categorical
variables and means (6SD) or median (with interquartile range)
for continuous variables. The hs-cTnT levels were presented both
as a continuous variable (after natural logarithmic transformation)
and as a categorical variable when appropriate. The hs-cTnT was
classified as undetectable (,3 pg/mL), and detectable ($3 pg/
mL). eGFR levels were categorized as: quartile 1 ($97.02 mL/
min/1.73 m
2), quartile 2 (97.01 to 87.76 mL/min/1.73 m
2),
quartile 3 (87.75 to 78.97 ml/min/1.73 m
2), and quartile 4
(#78.96 mL/min/1.73 m
2). The quartile 1 to 3 levels of eGFR
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quartile 4 level of eGFR was defined as the moderate to severe
reduced renal function. Statistical comparison of groups was
undertaken by one-way ANOVA (continuous variables) or chi-
square tests (categorical variables).
In order to evaluate the association between eGFR and hs-
cTnT as a continuous variable (natural logarithm transformed),
the Pearson’s correlation for continue variables or the Spearman’s
correlation for categorical variables was used in univariable
analyses, and multivariable linear regression analysis was per-
formed requiring a variable with a probability value of #0.10 to
be entered and ,0.05 to remain in the model after adjusting for
several potential confounders (covariates). In the analysis, unde-
tectable hs-cTnT levels (,3 pg/mL) were considered 1.5 pg/mL
[21].
In addition, to better understand the association between
different quartile levels of eGFR and detectable hs-cTnT, logistic
regression models were used. Forward stepwise multivariable
logistic regression was performed to obtain the odds ratios (OR)
and 95% confidence intervals (CI) requiring a variable with a
probability value of #0.10 to be entered and ,0.05 to remain in
the model and the quartile 1 level of eGFR was used as the
reference. Regression models were adjusted for high predicted
Framingham CHD risk (10-year risk $20%) (model 1) and for
model 1 plus levels of BMI, WC, and WHR (model 2). Model 3
was adjusted for model 2 plus levels of fasting glucose, uric acid,
hs-CRP, homocysteine and NT-proBNP.
Furthermore, in order to investigate the role of high predicted
Framingham CHD risk in the relationship between eGFR and hs-
cTnT, we evaluate the association between high predicted
Framingham CHD risk (10-year risk $20%) and detectable hs-
cTnT in subjects with different quartile levels of eGFR, forward
stepwise multivariable logistic regression was repeatedly used, a
variable with a probability value of #0.10 to be entered and
,0.05 to remain in the model. Regression models were adjusted
for BMI, WC, and WHR (model 1) and for model 1 plus levels of
fasting glucose, uric acid, hs-CRP, homocysteine and NT-proBNP
(model 2).
All data entry and management were undertaken on an Excel
spreadsheet and were then analyzed by the SPSS statistical
package (version 16.0; SPSS Inc., Chicago, IL, USA). A 2-sided
value of P,0.05 was considered significant.
Results
Clinical characteristics of participants
A total of 1365 subjects were included in the analysis. There
were 578 males (42.3%) and 787 females (57.7%). The age range
was 45 to 96 years old (mean, 62.3669.82 years). Of these, there
were 351 current smokers (25.7%), 239 DM patients (17.5%), 605
hypertensive individuals (44.3%). There were 28 subjects with
eGFR #60 ml/min/1.73 m
2 (1.89%).
Table 1 shows the clinical characteristics of the study
population. Participants were divided into four groups based on
the level of the quartile of eGFR ($97.02, 97.01–87.76, 87.75–
78.97, #78.96 mL/min/1.73 m
2). Compared to the quartile 1 of
eGFR, age, the percentage of hypertension and diabetes, the level
of SBP, total cholesterol, uric acid, homocysteine, hs-CRP, log
NT-proBNP, log hs-cTnT and high predicted Framingham CHD
risk score (10-year risk $20%) in the quartile 4 of eGFR were
higher (P,0.05).
Concentration and Distribution of hs-cTnT
The range of detectable hs-cTnT concentrations was 3.03–
176.40 pg/mL with a median value of 7.45 pg/mL (quartile 1 to
quartile 3: 4.84–12.02 pg/mL) in this community-based popula-
tion. Among 1365 participants, 621 subjects (45.5%) had
undetectable hs-cTnT (,3 pg/mL), 580 subjects (42.5%) had
hs-cTnT concentration 3–13.2 pg/mL, and 164 subjects (12.0%)
had hs-cTnT concentration $13.3 pg/mL.
The association between eGFR and hs-cTnT
The association between eGFR and hs-cTnT as a continuous
variable (natural logarithm transformed) was presented in table 2.
The results of Pearson’s correlation showed that eGFR had a
negative relationship with log hs-cTnT (r=20.143; P,0.001). In
multivariable linear regression analysis, eGFR was negatively and
independently associated with hs-cTnT levels. In addition, the
male, older age, NT-proBNP and fasting glucose were positively
and independently associated with hs-cTnT levels.
The relationship between different quartile levels of eGFR and
detectable hs-cTnT is shown in Tables 3. A stepwise logistic
regression model was performed and the quartile 1 level of eGFR
was used as the reference. In the univariate model, all quartile
levels of eGFR were associated with detectable hs-cTnT. After
adjusted for high predicted Framingham CHD risk (10-year risk
$20%) and/or other predicted factors, however, only quartile 4 of
eGFR was independently associated with detectable hs-cTnT.
eGFR in quartile 2 and 3 were not independently associated with
detectable hs-cTnT in the adjusted models (Model 1, 2 and 3).
Tables 4 shows the relationship between the high predicted
Framingham CHD risk (10-year risk $20%) and hs-cTnT value as
a categorical variable (detectable or undetectable) in subjects with
different quartile levels of eGFR. The results showed that the high
Framingham CHD risk score was independently associated with
detectable hs-cTnT in adjusted models (Modle 1, 2). Furthermore,
the OR increased with decreasing quartile levels of eGFR
(quartiles 1 to 3), whereas the OR decreased abruptly in the
quartile 4 of eGFR.
Discussion
In this study, we demonstrated for the first time that, moderate-
to-severe reduced eGFR (the level of quartile 4 of eGFR) was
independently and negatively associated with detectable hs-cTnT.
In contrast, normal-to-mild reduced eGFR (the level of quartile 1
to 3 of eGFR) was not independently associated with detectable hs-
cTnT. Moreover, the high predicted Framingham CHD risk (10-
year risk $20%) was independently and positively associated with
detectable hs-cTnT in different quartile levels of eGFR. These
results indicate that high predicted Framingham CHD risk maybe
play a dominant role to affect the level of hs-cTnT in normal-to-
mild reduced renal function, however, high predicted Framing-
ham CHD risk and eGFR were conjunctly associated with
detectable hs-cTnT in moderate-to-severe reduced renal function.
The mechanisms responsible for the release of very low levels of
cTnT in the general population could include subclinical
myocardial damage [22], inflammatory processes [23], reduced
renal clearance and so on. Of there, subclinical myocardial
damage may be the principal cause. The cTnT is an extremely
sensitive and specific biomarker of myocardial necrosis [24].
Normally, the majority of troponin exists as a tripartite complex of
C, I, and T components that are bound to actin filaments, and the
remainder is free in the cytoplasm. When cardiomyocyte damage
occurs, the cytoplasmic pool of troponin is released first and
followed by a more protracted release from stores bound to
eGFR and hs-cTnT in a Community-Based Population
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highly sensitive assay in subclinical myocardial damage, which is
even in slight injury. However, few data are available for
evaluating the prevalence of cTnT elevation in a large and
representative sample of the general population because of the low
sensitivity of the conventional assay system [7]. With the use of this
highly sensitive assay, identification of subclinical myocardial
damage is improved. In the present study, we found that
circulating hs-cTnT levels were detectable in 54.5% of subjects
and <12.0% of subjects had hs-cTnT concentrations $13.3 pg/
mL. The results are similar to other studies [26,27].
The interaction between the heart and kidney has been
explored for a long time. Several studies have documented that
patients with a progressive decrease in eGFR are at a higher risk of
cardiovascular disease than the general population, and show a
higher prevalence of cardiovascular mortality [28–30]. Levels of
cTnT are frequently elevated in the absence of acute coronary
occlusion among patients with renal dysfunction, specifically in
30–75% of end-stage renal disease patients [31–32]. However, the
pathophysiologic mechanisms causing random increases in cTnT
levels in patients with renal dysfunction or dialysis are unclear.
Several reasons may help to explain this correlation. Firstly, with
reduced of renal excretion, increase of volume load [33] or
accumulation of a certain nephrotoxin per se [34] would lead to
ischemia or damage to the myocardium. Secondly, troponin is
usually believed to be cleared by the reticuloendothelial system
given the relatively large molecular size of troponin [35].
However, recent evidence demonstrates that troponin T can be
fragmented into molecules small enough to be excreted by the
kidney; this may explain the high prevalence of troponin elevation
in patients with severe renal failure [36]. Thirdly, with decreased
renal function, the cardiovascular risk is increased and the
possibility of subclinical myocardial damage raised [37]. In the
present study, after stepwise adjustment for high predicted
Framingham CHD risk and other cardiovascular prognostic
indicators, such as BMI, NT-proBNP, hs-CRP, homocysteine
and so on, normal-to-mild reduced levels of eGFR were not
independently associated with detectable hs-cTnT. In contrast,
moderate-to-severe reduced levels of eGFR were independently
and negatively associated with detectable hs-cTnT. The results
Table 1. The clinical characteristics of study participants.
Overall Quartile 1 Quartile 2 Quartile 3 Quartile 4
(n=1365) $97.02 97.01-87.76 87.75-78.97 #78.96
Characteristic (n=342) (n=341) (n=341) (n=341)
eGFR (ml/min/1.73 m
2) 87.76(78.98,97.03) 107.36(100.45,115.98) 91.74(89.47,93.99)
* 83.47(81.14,85.68)
* 72.04(67.24,75.99)
*
Age (years) 62.3669.82 60.5169.64 59.0568.93 62.0469.54 67.8468.83
#
male sex [n (%)] 578(42.3%) 138(40.4%) 146(42.8%) 143(41.3%) 151(44.3%)
BMI (kg/m
2) 25.6163.51 25.5363.56 25.6563.68 25.5463.40 25.7363.41
WC (cm) 86.9069.78 86.2969.92 86.85610.27 86.5969.70 87.9069.17
Waist-hip ratio 0.8760.06 0.8760.06 0.8760.06 0.8760.07 0.8860.06
Current smoking [n (%)] 351(25.7%) 91(26.6%) 80(23.5%) 85(24.9%) 95(27.9%)
Hypertension [n (%)] 605(44.3%) 143(41.8%) 135(39.6%) 158(46.3%)
* 169(49.6%)
*
Diabetes mellitus [n (%)] 239(17.5%) 78(22.8%) 53(15.5%)
* 52(15.2%)
* 56(16.4%)
*
Systolic BP (mm Hg) 130.79618.20 129.00618.29 128.77618.34 132.07617.18
* 133.31618.60
*
Diastolic BP (mm Hg) 76.86610.71 77.51610.84 77.38610.66 76.5269.81 76.04611.45
Total cholesterol (mmol/L) 5.0760.91 4.9360.90 5.0960.87 5.1060.93 5.1860.92
#
Triglyceride (mmol/L) 1.8161.22 1.7861.01 1.8561.29 1.8061.37 1.8161.21
HDL cholesterol (mmol/L) 1.4060.36 1.4160.39 1.4160.36 1.4360.35 1.3760.35
LDL cholesterol (mmol/L) 2.9960.70 2.9660.66 2.9760.70 3.0160.73 3.0160.72
Fasting glucose (mmol/L) 5.4261.68 5.5662.10 5.4861.43 5.3961.72
* 5.2861.37
*
Uric acid (mmol/L) 291.31673.10 269.88671.47 280.42665.60
# 297.31672.78
# 317.71673.45
#
Homocysteine (mmol/L) 19.1668.56 17.6967.33 18.0567.61 18.7968.58 22.1269.81
#
hs-CRP (mg/dL) 0.22(0.14,0.34) 0.20(0.14,0.33) 0.21(0.12,0.33) 0.23(0.13,0.36) 0.25(0.16,0.36)
#
Log NT-proBNP (pg/mL) 3.72(2.95,4.39) 3.54(2.86,4.22) 3.48(2.67,4.21) 3.72(2.94,4.32)
# 4.14(3.42,4.85)
#
Log hs-cTnT (pg/mL) 1.27(1.10,2.08) 1.10(1.10,1.94) 1.10(1.10,1.91) 1.26(1.10,2.13)
# 1.67(1.10,2.31)
#
Framingham risk score, % 9.00(6.00,15.00) 9.00(5.00,14.00) 8.00(5.00,13.00) 9.00(6.00,14.00) 11.00(7.00,18.00)
#
Framingham risk score $20, no. (%) 202(14.8%) 48(14.0%) 35(10.34%) 46(13.5%) 72(21.1%)
#
Note: Characteristics are reported as percentages for categorical variables and means (6SD) or median (with interquartile range) for continuous variables. The study
participants were divided into four groups based on the level of the quartile of eGFR ($97.02, 97.01–87.76, 87.75–78.97, #78.96 mL/min/1.73 m
2). Categorical variables
are presented as counts and percentages. The values outside the parentheses are the number of subjects, and the values inside the parentheses are prevalence.
The quartile 1 level of eGFR was used as the reference and the quartile 2,3,4 vs the quartile 1, respectively.
*,0.05 vs Quartile 1,
#,0.01 vs Quartile 1.
eGFR, estimated glomerular filtration rate; hs-cTnT denotes high-sensitivity cardiac troponin T; BMI, bodymass index; WC, waist circumference; BP, blood pressure; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro B-type.
doi:10.1371/journal.pone.0038218.t001
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cTnT in normal-to-mild reduced renal function. While, high
predicted Framingham CHD risk (representing traditional cardio-
vascular risk factors) perhaps is the important ‘‘other factors’’.
Then in order to investigate the role of the predicted
Framingham CHD risk in the relationship between eGFR and
hs-cTnT, we evaluate the association between high predicted
Framingham CHD risk (10-year risk $20%) and detectable hs-
cTnT in subjects with different quartile levels of eGFR. The results
showed that the high predicted Framingham CHD risk was
independently associated with detectable hs-cTnT in different
levels of eGFR in adjusted models. Furthermore, the OR for high
predicted CHD risk increased with decreasing quartile levels of
eGFR (quartiles 1 to 3) in normal-to-mild reduced renal function
groups. However, the OR for high predicted Framingham CHD
risk was abruptly decreased in the moderate-to-severe reduced
renal function group (quartile 4). The results indicated that the
association between high predicted Framingham CHD risk and
detectable hs-cTnT gradually strengthened with decreasing levels
of eGFR in normal-to-mild reduced renal function. However, this
kind of association was weakened in moderate-to-severe reduced
renal function. Combined with the results of table 3, one possible
and reasonable explanation for the abruptly decreasing of OR was
that eGFR had an effect on detectable hs-cTnT in moderate-to-
severe reduced renal function. In other words, we thought that the
high predicted Framingham CHD risk was independently
associated with detectable hs-cTnT in all levels of eGFR, while
reduced level of eGFR as an independent factor was added on
high predicted Framingham CHD risk in association with
detectable hs-cTnT in moderate-to-severe reduced renal function.
Our study was a cross-sectional survey and, as such, did not
have the ability to determine the causes of hs-cTnT elevation in
the context of impaired renal function. But our results suggest that
sub-clinical myocardial injury due to cardiovascular risk factors
(indicated by the high predicted Framingham CHD risk) maybe
play a dominant role in hs-cTnT elevation. Our data also suggest
that reduced hs-cTnT clearance was not independently associated
with hs-cTnT elevations in subjects with normal or mildly reduced
renal function. However, in the context of severely impaired renal
function, both increased sub-clinical myocardial injury and
reduced hs-cTnT clearance may be responsible for elevated hs-
cTnT levels. This is a complex issue and further studies are needed
to clarify these relationships.
In the present study, GFR was estimated by modifying the
MDRD equation based on data from a Chinese population. It
offered significant advantages in different stages of chronic kidney
disease (CKD). In particular, underestimation of GFR in CKD
stages 1–2 was significantly improved, resulting in a lower
overestimation of prevalence of reduced renal function if used in
a Chinese population [19]. By using this equation, the prevalence
of moderate-to-severe reduced renal function in our study was
estimated to be 1.89%. This value was similar to the result from
another community-based study in China in which the prevalence
of decreased renal function was 1.7% [38].
The small number of the community-based population was
limitation in the present study and these participants may not be
fully representative of the general population. Moreover, the study
population was Chinese and renal function was estimated by C-
MDRD. Therefore, extrapolation of our results to other demo-
Table 2. Pearson’s correlation and Multiple linear regression
analysis for the association between eGFR and the hs-cTnT
levels.
Characteristic Univariable Multivariable
r P Value b P Value
Age, yr 0.213 ,0.001 0.112 ,0.001
Male sex 0.240 ,0.001 0.200 ,0.001
Hypertension 0.135 ,0.001 … …
Diabetes mellitus 0.121 ,0.001 … …
Current smoking 0.085 0.002 … …
BMI, kg/m
2 0.022 0.409 … …
Systolic BP, mm Hg 0.078 0.004 … …
Diastolic BP, mm Hg 20.034 0.208 … …
Total cholesterol, mmol/L 20.056 0.039 … …
Triglyceride, mmol/L 20.005 0.853 … …
HDL cholesterol, mmol/L 20.110 ,0.001 … …
LDL cholesterol, mmol/L 0.023 0.401 … …
Fasting glucose, mmol/L 0.067 0.013 0.098 ,0.001
hs-CRP, mg/L 0.019 0.472 … …
Uric acid, mmol/L 0.136 ,0.001 … …
Homocysteine, mmol/L 0.194 ,0.001 … …
NT-proBNP, pg/mL 0.116 ,0.001 0.169 ,0.001
eGFR, mL/min/1.73 m
2 20.143 ,0.001 20.069 0.009
Note: High-sensitivity cardiac troponin T levels were natural logarithm
transformed. BMI, body-mass index; BP, blood pressure; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive
protein; NT-proBNP, N-terminal pro B-type natriuretic peptide; eGFR, estimated
glomerular filtration rate.
doi:10.1371/journal.pone.0038218.t002
Table 3. Association between eGFR and detectable hs-cTnT.
Quartile 1 Quartile 2 Quartile 3 Quartile 4
$97.02 97.01-87.76 87.75-78.97 #78.96
Univariable model
Odds ratio 1 1.016 1.573 2.164
95% CI Reference 1.002–1.019 1.208–2.049 1.610–2.909
P 0.020 0.001 ,0.001
Model 1
Odds ratio 1 1.036 1.261 2.069
95% CI Reference 0.774–1.386 0.942–1.689 1.531–2.796
P 0.813 0.119 ,0.001
Model 2
Odds ratio 1 1.019 1.175 1.950
95% CI Reference 0.753–1.380 0.869–1.590 1.427–2.663
P 0.903 0.294 ,0.001
Model 3
Odds ratio 1 1.016 1.080 1.500
95% CI Reference 0.746–1.382 0.793–1.471 1.078–2.086
P 0.922 0.625 0.016
Note:
Model 1: Adjusted for the high predicted Framingham CHD risk (10-year risk
.20%).
Model 2: Adjusted for model 1 plus levels of body mass index; waist
circumference and waist-hip ratio.
Model 3: Adjusted for model 2 plus levels of fasting glucose, uric acid, high-
sensitivity C-reactive protein, homocysteine and NT-proBNP.
doi:10.1371/journal.pone.0038218.t003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e38218graphic groups should be done with caution. This study was a
cross-sectional survey and had no capability to get the cause and
effect, so more exact conclusions should be confirmed by a
prospective study.
In conclusion, hs-cTnT levels are detectable with a highly
sensitive assay in a community-based Chinese population. Renal
function is associated with hs-cTnT levels. eGFR levels and the
high predicted Framingham CHD risk are conjunctly associated
with detectable hs-cTnT in moderate-to-severe reduced renal
function. Further, large and well-conducted studies are urgently
required to provide more definitive evidence.
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